Co-trimoxazole to reduce mortality, transplant, or unplanned hospitalisation in people with moderate to very severe idiopathic pulmonary fibrosis: the EME-TIPAC RCT

Co-trimoxazole to reduce mortality, transplant, or unplanned hospitalisation in people with moderate to very severe idiopathic pulmonary fibrosis: the EME-TIPAC RCT

Background: Idiopathic pulmonary fibrosis is an irreversible fibrosing lung disorder with a poor prognosis. Current treatments slow the rate of decline in lung function and may influence survival, but they have a significant side-effect profile and so additional therapeutic options are required. Peo...

Full description

Bibliographic Details
Main Authors: Andrew M Wilson, Allan B Clark, Anthony Cahn, Edwin R Chilvers, William Fraser, Matthew Hammond, David M Livermore, Toby M Maher, Helen Parfrey, Ann Marie Swart, Susan Stirling, David Thickett, Moira Whyte
Format: Article
Language:English
Published: NIHR Journals Library 2021-07-01
Series:Efficacy and Mechanism Evaluation
Subjects:
idiopathic pulmonary fibrosis
co-trimoxazole
mortality
hospitalisation
cough
randomised controlled trial
Online Access:https://doi.org/10.3310/eme08090

Internet

https://doi.org/10.3310/eme08090

Similar Items